CIRRX
Price
$19.63
Change
-$0.05 (-0.25%)
Updated
Aug 21 closing price
Net Assets
9.87B
RYREX
Price
$44.16
Change
-$0.05 (-0.11%)
Updated
Aug 21 closing price
Net Assets
4.21M
Interact to see
Advertisement

CIRRX vs RYREX

CIRRX vs RYREX Comparison Chart in %
View a ticker or compare two or three
VS
CIRRX vs. RYREX commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CIRRX is a Hold and RYREX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CIRRX has more cash in the bank: 9.87B vs. RYREX (4.21M). RYREX pays higher dividends than CIRRX: RYREX (3.15) vs CIRRX (1.39). CIRRX was incepted earlier than RYREX: CIRRX (12 years) vs RYREX (22 years). RYREX (1.70) is less costly to investors than CIRRX (1.25). RYREX is a more actively managed with annual turnover of: 1408.00 vs. CIRRX (27.00). CIRRX has a lower initial minimum investment than RYREX: CIRRX (0) vs RYREX (2500). CIRRX annual gain was more profitable for investors over the last year : 14.19 vs. RYREX (11.97). CIRRX return over 5 years is better than : 8.30 vs. RYREX (6.51).
CIRRXRYREXCIRRX / RYREX
Total Expense Ratio1.251.6576%
Annual Report Gross Expense Ratio1.251.7074%
Fund Existence12 years22 years-
Gain YTD14.86511.571128%
Front LoadN/A5%-
Min. Initial Investment02500-
Min. Initial Investment IRAN/AN/A-
Net Assets9.87B4.21M234,434%
Annual Yield % from dividends1.393.1544%
Returns for 1 year14.1911.97119%
Returns for 3 years40.2036.29111%
Returns for 5 years8.306.51127%
Returns for 10 years57.1744.28129%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GOIGX38.740.45
+1.18%
JHancock International Growth A
GQSIX19.900.20
+1.02%
Glenmede Disciplined U.S. Sm Cp Eq Instl
GATAX52.960.50
+0.95%
Gabelli Asset A
WFEIX65.330.49
+0.76%
Allspring Mid Cap Growth Fund - Cl Inst
AIGGX15.930.05
+0.31%
Aristotle Growth Equity I-2